tremelimumab
Selected indexed studies
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. (NEJM Evid, 2022) [PMID:38319892]
- Tremelimumab. (, 2012) [PMID:36795905]
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. (J Clin Oncol, 2023) [PMID:36327426]
_Worker-drafted node — pending editorial review._
Connections
tremelimumab is a side effect of
Sources
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. (2022) pubmed
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. (2023) pubmed
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. (2021) pubmed
- Tremelimumab. (2012) pubmed
- Tremelimumab: First Approval. (2023) pubmed
- Tremelimumab. (2006) pubmed
- Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. (2025) pubmed
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. (2024) pubmed
- Tremelimumab for the treatment of hepatocellular carcinoma. (2025) pubmed
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial. (2025) pubmed